Candel Therapeutics' CAN-2409 delivers durable benefit in positive phase 3 prostate cancer trial

By Proactive Investors / October 02, 2025 / www.youtube.com / Article Link


Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to highlight new subgroup analyses from the ...

Recent News

Market still expecting strong growth for major gold producers
July 27, 2026 / www.canadianminingreport.com

Newmont starts Q2/26 strong, growth expected for gold majors
July 27, 2026 / www.canadianminingreport.com

Gold not the consensus play anymore
July 20, 2026 / www.canadianminingreport.com

Gold stocks drop to lowest levels this year
July 20, 2026 / www.canadianminingreport.com

A rebalancing of gold's ratios versus major commodities
July 14, 2026 / www.canadianminingreport.com
See all >
Share to Youtube Share to Facebook Facebook Share to Linkedin Share to Twitter Twitter Share to Tiktok